Idexx Laboratories stock hits 52-week high at $530.74

June 24, 2025 12:59 PM PDT | By EODHD

Google News:

Idexx Laboratories stock hits 52-week high at $530.74 — Image source: Kalkine Media

Recent News

Deribit and SignalPlus Launch “The Summer Chase” Trading Competition 2...

Analysis: Strait of Hormuz transit steady, but freight rates could kee...

Trump says he is considering 3 or 4 people to succeed Powell as Fed ch...

Boy, that escalated quickly!

Idexx Laboratories (NASDAQ:IDXX) Inc. stock reached a new 52-week high, touching $530.74 during recent trading sessions. According to InvestingPro data, the company, valued at $42.6 billion, is currently trading above its Fair Value, suggesting investors should monitor valuation levels carefully. This milestone reflects a positive trajectory for the company, which has seen its stock value increase by 7.87% over the past year. The veterinary diagnostics company has been experiencing steady growth, with revenue increasing by 5.56% in the last twelve months, driven by strong demand for its products and services in the animal healthcare sector.

With an impressive financial health score rated as "GREAT" by InvestingPro, and operating with moderate debt levels, this upward trend in stock price underscores investor confidence in Idexx Laboratories’ continued expansion and innovation within the industry. InvestingPro subscribers have access to 16 additional key insights about IDXX, including detailed valuation metrics and growth indicators. In other recent news, IDEXX Laboratories reported its first-quarter 2025 earnings, with an earnings per share (EPS) of $2.96, surpassing analyst expectations of $2.86. The company’s revenue for the quarter was $998.43 million, slightly below the anticipated $1 billion. IDEXX’s organic revenue growth was 5%, supported by the launch of new products like the IDEXX CancerDx for canine lymphoma detection.

The company has also updated its full-year EPS guidance to a range of $11.93 to $12.43 per share. Analysts from Leerink Partners and BTIG have shown optimism in IDEXX’s growth, with Leerink raising the stock price target to $580 and BTIG increasing it to $545, both maintaining positive ratings. BTIG highlighted IDEXX’s ability to navigate economic challenges and improve its margins, while Leerink emphasized the company’s strong position in the veterinary diagnostics market. IDEXX’s recent product innovations and strategic management are seen as key drivers for its continued growth. This article was generated with the support of AI and reviewed by an editor.

For more information see our T&C.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.